Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Adverum Biotechnologies

Evaluate

Thumbnail
October 24, 2022

Syncona sets its sights on a gene therapy turnaround

But, with Applied Genetic Technologies Corporation, can lightning strike a third time?

Thumbnail
February 14, 2022

Angiogenesis 2022 – Regeneron and Bayer see positive signs for long-acting Eylea

The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold?

Article image
Vantage logo
July 23, 2021

Adverum eyes disaster

Article image
Vantage logo
July 22, 2021

Roche takes the Tim-3 battle to Novartis

The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.

Article image
Vantage logo
June 16, 2021

Clearside’s long-acting eye project shows promise

But data are early, and other groups are also developing less frequent injections for wet AMD.

Article image
Vantage logo
June 15, 2021

Nightstar becomes nightmare, but Biogen has bigger fish to fry

A second clinical failure means that Biogen threw away $877m, but this sum will today be seen as little more than a rounding error.

Article image
Vantage logo
April 29, 2021

Adverum halt raises more gene therapy questions

A serious adverse event puts ADVM-022’s future in doubt, and it could hurt other eye disease gene therapy players too.

Article image
Vantage logo
December 19, 2019

Gene therapy clinical holds take centre stage

An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.

Article image
Vantage logo
September 12, 2019

Adverum cannot hide under an avalanche of concerns

Article image
Vantage logo
August 09, 2018

Shire dodges pricing questions as lanadelumab’s big day nears

Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?

Vantage logo
January 02, 2018

Interview – Mereo’s quest for diamonds in the rough

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up